Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis

Antiviral Therapy

Volumn 10, Issue 6, 2005, Pages 709-713

  Viganò, Mauro ^a   Colombo, Massimo ^a   Aroldi, Adriana ^a   Lunghi, Giovanna ^a   Manenti, Elena ^a   Ponticelli, Claudio ^a   Lampertico, Pietro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; CYCLOSPORIN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; TACROLIMUS; VIRUS DNA;

ADULT; ARTICLE; BLOOD LEVEL; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENOTYPE; HEMODIALYSIS; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION; LONG TERM CARE; MALE; MONOTHERAPY; PRIORITY JOURNAL; RECIPIENT; SEPSIS;

ADULT; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 25444524337     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Gane E & Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74:427-437.
2. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P & Bitker MO. Impact of hepatitis B and C on kidney transplantation outcome. Hepatology 1999; 29:257-263.
3. Degos F, Lugassy C, Degott C, Debure A, Carnot F, Theirs V, Tiollais P, Kreis H & Brechot C. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. Gastroenterology 1997; 97:151-156.
4. Fornairon S, Pol S, Legendre C, Carnot F, Mamzer-Bruneel MF, Brechot C & Kreis H. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996; 62:297-299.
5. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH & Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74:512-516.
6. Conjeevaram HS, Lok AS. Management of chronic hepatitis B. Journal of Hepatology 2003; 38:590-103.
7. Rostaing L, Henry S, Cisterne JM, Duffaut M, Icart J & Durand D. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64:1624-1627.
8. Goffin E, Horsmans Y, Cornu C, Squifflet JP & Pirson Y. Lamivudine inhibits hepatitis B virus replication in kidney graft recipients. Transplantation 1998; 66:407-409.
9. Jung YO, Lee YS, Yang WS, Han DJ, Park JS, Park SK. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Transplantation 1998; 66:733-737
10. Mouquet C, Bernard B, Poynard T, Thibault V, Opolon P, Coriat P & Bitker MO. Chronic hepatitis B treatment with lamivudine in kidney transplant patients. Transplantation Proceedings 2000; 32:2762.
11. Fontaine H, Thiers V, Chretien Y, Zylberberg H, Poupon RE, Brechot C, Legendre C, Kreis H & Pol S. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000; 69:2090-2094.
12. Kletzmayr J, Watschinger B, Muller C, Demetriou D, Puchhammer-Stockl E, Ferenci P & Kovarik J. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation 2000; 70:1404-1407.
13. + renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001; 71:387-394.
14. Park SK, Yang WS, Lee YS, Jung HH, Chang JJ, Choi HJ, Han DJ & Park JS Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. Nephrology Dialysis Transplantation 2001; 16:2222-2228.
15. Schvoerer E, Kabissa I, Cotto E, Jouvencel AC, Balabaund C, De Ledinghen V, Couzigou P, Quinton A, Schvoerer C, Lafon ME, Fleury H & Bernard PH. Lamivudine therapy of chronic hepatitis B in the three groups of patients: non transplant patients, liver recipients and kidney recipients. Gastroenterologie Clinique et Biologique 2002; 26:62-66.
16. Tsang WK, Tong KL & Chan HWH. Lamivudine therapy in renal allograft recipients with hepatitis B virus infection. Transplantation Proceedings 2003; 35:278-279.
17. Chan TM, Tse KC, Tang CSO, Lai KN & Ho SKN. Prospective study on lamivudine-resistant hepatitis B in renal allograft recipients. American Journal of Transplantation 2004; 4:1103-1109.
18. EASL Jury. EASL International Consensus Conference on Hepatitis B. Journal of Hepatology 2003; 39:S3-S25.
19. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M & Rodes J; EASL Panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. Journal of Hepatology 2001; 35:421-430.
20. Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G & Rossau R. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. Journal of Clinical Microbiology 2000; 38:702-707.
21. Fontana RJ & Lok AS. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis. Journal of Hepatology 2000; 33:329-332.
22. Fabrizi F, Dulai G, Dixit V, Bunnapradist S & Martin P. Lamivudine for the treatment of hepatitis B virus related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004; 77:859-864.
23. Thabut D, Thibault V, Bernard-Chabert B, Mouquet C, Di Martino V, Le Calvez S, Opolon P, Benhamou Y, Bitker MO & Poynard T. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. European Journal of Gastroenterology and Hepatology 2004; 16:1367-1373.
24. Kamar N, Sandres-saune K, Ribes D, Duffaut M, Selves J, Durand D, Izopet J & Rostaing L. Effects of long-term lamivudine therapy in renal-transplant patients. Journal of Clinical Virology 2004; 31:298-303.
25. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, Rizzetto M & Craxì A for the Italian Association for the Study of the Liver (AISF) Lamivudine Study Group. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40:883-891.
26. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD & Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-1722.
27. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A & Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847-851.
28. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F & Ferrari C. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. Journal of Clinical Investigation 1998; 102:867-868.